**Supplementary Table S6. Kaplan-Meier estimates of clinical outcome according to mutation status and primary tumour sidedness**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Total study population**  **(*n* = 528)** | | ***RAS/BRAF* WT**  **(*n* = 133)** | | ***RAS* MTa**  **(*n* = 233)** | | **V600E*BRAF* MTb**  **(*n* = 28)** | |
|  | **Right** | **Left** | **Right** | **Left** | **Right** | **Left** | **Right** | **Left** |
|  | ***n* = 122** | ***n* = 406** | ***n* = 16** | ***n* = 117** | ***n* = 62** | ***n* = 171** | ***n* = 20** | ***n* = 8** |
| **PFS1** | | | | | | | | |
| Events | 118 | 397 | 16 | 114 | 61 | 170 | 18 | 6 |
| Median (months) | 4.2 | 5.9 | 5.7 | 6.3 | 4.1 | 5.2 | 4.3 | 5.7 |
| 95% CI | 3.6-4.9 | 5.4-6.4 | 0.0-13.2 | 4.9-7.7 | 3.8-4.4 | 4.1-6.4 | 2.6-6.1 | 0.0-12.8 |
| *P*-valuec | 0.381 | | 0.749 | | 0.465 | | 0.487 | |
| **PFS2** | | | | | | | | |
| Events | 117 | 396 | 16 | 113 | 60 | 170 | 18 | 6 |
| Median (months) | 8.4 | 10.7 | 11.1 | 11.1 | 8.3 | 10.7 | 8.4 | 5.7 |
| 95% CI | 6.4-10.5 | 9.6-11.7 | 4.1-18.1 | 8.9-13.2 | 5.2-11.3 | 9.3-12.0 | 4.9-11.9 | 0.0-16.3 |
| *P*-valuec | 0.403 | | 0.870 | | 0.711 | | 0.469 | |
| **TT2PD** | | | | | | | | |
| Events | 117 | 392 | 16 | 112 | 60 | 169 | 18 | 6 |
| Median (months) | 10.5 | 13.2 | 13.4 | 13.5 | 11.1 | 13.3 | 8.4 | 13.0 |
| 95% CI | 8.2-12.8 | 12.3-14.1 | 6.9-19.8 | 11.4-15.5 | 7.5-14.6 | 11.7-14.8 | 4.9-11.9 | 0.0-27.3 |
| *P*-valuec | 0.163 | | 0.617 | | 0.476 | | 0.383 | |
| **OS** | | | | | | | | |
| Events | 117 | 388 | 16 | 111 | 60 | 167 | 18 | 6 |
| Median (months) | 15.7 | 21.8 | 21.7 | 24.3 | 16.5 | 21.6 | 11.8 | 15.7 |
| 95% CI | 13.1-18.2 | 20.2-23.5 | 16.8-26.6 | 21.5-27.1 | 13.2-19.8 | 19.7-23.5 | 7.6-16.0 | 8.3-23.1 |
| *P*-valuec | 0.010 | | 0.574 | | 0.127 | | 0.314 | |

CI = confidence interval. MT = mutant. WT = wild-type. Patients with primary tumour location ‘colon n.o.s.’ or ‘multiple sites’ were excluded from the analysis. a Two patients with concomitant *BRAF* MT tumour excluded. b One patient with concomitant *RAS* MT tumour excluded. c *P*-value for overall comparison between patients with right-sided and left-sided tumours.